Get the Stockscreener App
9.07
0.44%
0.04
Pre-market:
9.07
Lenz Therapeutics Inc stock is traded at $9.07, with a volume of 1.42M.
It is up +0.44% in the last 24 hours and down -31.39% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$9.03
Open:
$9.19
24h Volume:
1.42M
Relative Volume:
1.46
Market Cap:
$283.80M
Revenue:
$17.50M
Net Income/Loss:
$-58.88M
P/E Ratio:
-4.3037
EPS:
-2.1075
Net Cash Flow:
$-46.16M
1W Performance:
-22.61%
1M Performance:
-31.39%
6M Performance:
-77.34%
1Y Performance:
-65.68%
1-Day Range:
$8.99
$9.39
1-Week Range:
$8.85
$11.88
52-Week Range:
$8.85
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
9.07 | 282.55M | 17.50M | -58.88M | -46.16M | -2.1075 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
Valuation Update: What is the cash position of LENZ Therapeutics Inc2026 Market Outlook & Daily Profit Focused Stock Screening - baoquankhu1.vn
LENZ Therapeutics Hits 52-Week Low at $8.86 Amid Ongoing Struggles - Markets Mojo
Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price - MarketBeat
LENZ Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
LENZ Therapeutics Reports Fourth Quarter, Full-Year Financial Results as Sales of Presbyopia Drop Gain Momentum - VisionMonday.com
VIZZ by LENZ Therapeutics: FDA-Approved Once-Daily Eye Drop for Presbyopia Treatment and Market Opportunity 32 - Minichart
LENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.25 EPS - MarketBeat
LENZ Therapeutics 2025 10-K: $19.1M Revenue, $(2.85) EPS - TradingView
LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
LENZ: Initial VIZZ launch drove $1.6M sales and $17.5M license revenue, but net loss reached $82.1M - TradingView
VIZZ presbyopia launch propels LENZ Therapeutics (NASDAQ: LENZ) - Stock Titan
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates - MSN
Earnings call transcript: LENZ Therapeutics Q4 2025 sees stock dip amid high expenses - Investing.com UK
LENZ Therapeutics Reports Q4 and Full Year 2025 Results; Launches VIZZ Eye Drop for Presbyopia with Strong Prescription Uptake and Expanding Commercial Infrastructure - Minichart
LENZ Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Why Lenz Therapeutics Stock Crashed Today - The Globe and Mail
LENZ Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: LENZ Therapeutics Q4 2025 sees stock dip amid high expenses By Investing.com - Investing.com India
LENZ: Strong launch momentum, robust cash, and expanding adoption position the product for growth - TradingView
Why Lenz Therapeutics Stock Crashed Today - The Motley Fool
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch - ChartMill
LENZ Therapeutics, Inc. (LENZ) Reports Wider Q4 Loss Than Expected - AlphaStreet
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
LENZ Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
LENZ THERAPEUTICS ($LENZ) Releases Q4 2025 Earnings - Quiver Quantitative
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - The Manila Times
VIZZ launch drives first LENZ (NASDAQ: LENZ) product revenue in 2025 - Stock Titan
LENZ: VIZZ launch drove $1.6M in Q4 sales; net loss rose to $82.1M amid major launch investments - TradingView
LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.9... - Benzinga
LENZ Therapeutics Hits 52-Week Low at USD 11.22 Amidst Declining Performance - Markets Mojo
LENZ Therapeutics Hits 52-Week Low at USD 10.44 Amid Ongoing Struggles - Markets Mojo
LENZ Therapeutics, Inc. (LENZ) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Top Wall Street forecasters revamp LENZ Therapeutics expectations ahead of Q4 earnings - MSN
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen - MarketBeat
LENZ Therapeutics Inc expected to post a loss of 97 cents a shareEarnings Preview - TradingView
Can LENZ Therapeutics Inc. be the next market leader2026 Big Picture & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026 - The Manila Times
Maker of VIZZ presbyopia eye drop sets March 24 call on 2025 results - Stock Titan
IPO Launch: Is LENZ Therapeutics Inc affected by consumer sentimentMarket Rally & AI Driven Stock Movement Reports - baoquankhu1.vn
693,044 Shares in LENZ Therapeutics, Inc. $LENZ Acquired by First Light Asset Management LLC - MarketBeat
LENZ Therapeutics, Inc. $LENZ is Ally Bridge Group NY LLC's 7th Largest Position - MarketBeat
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
Performance Recap: Can LENZ Therapeutics Inc reach all time highs this year2026 Historical Comparison & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
LENZ Therapeutics Projected to Post Earnings on WednesdayDel Mar Today - National Today
LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday - MarketBeat
William Blair Maintains Outperform on LENZ Therapeutics, Inc (LENZ) March 10 2026 - Meyka
LENZ submits marketing application for presbyopia drug in Europe - Investing.com South Africa
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential By Investing.com - Investing.com Canada
LENZ submits marketing application for presbyopia drug in Europe By Investing.com - Investing.com Australia
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):